C-reactive protein and fracture risk: European Prospective Investigation into Cancer Norfolk Study

Bone

Volumn 56, Issue 1, 2013, Pages 67-72

  Ahmadi Abhari, Sara ^a   Luben, Robert N ^a   Wareham, Nicholas J ^b   Khaw, Kay Tee ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

Author keywords

Ageing; C reactive protein; Cohort study; Fracture; Inflammation; Osteoporosis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ARTHRITIS; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; FRACTURE; HEART INFARCTION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL HISTORY; OSTEOPOROSIS; PHYSICAL ACTIVITY; POPULATION RISK; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING HABIT;

AGEING; C-REACTIVE PROTEIN; COHORT STUDY; FRACTURE; INFLAMMATION; OSTEOPOROSIS;

ADULT; AGED; C-REACTIVE PROTEIN; FEMALE; FRACTURES, BONE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84879285539     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.05.009     Document Type: Article

References (45)

1. De M.M., Franceschi C., Monti D., Ginaldi L. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 2006, 80:219-227.
2. De M.M., Franceschi C., Monti D., Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 2005, 579:2035-2039.
3. Goto M. Inflammaging (inflammation+aging): a driving force for human aging based on an evolutionarily antagonistic pleiotropy theory?. Biosci Trends 2008, 2:218-230.
4. Ostan R., Bucci L., Capri M., Salvioli S., Scurti M., Pini E., et al. Immunosenescence and immunogenetics of human longevity. Neuroimmunomodulation 2008, 15:224-240.
5. Kaptoge S., Di A.E., Lowe G., Pepys M.B., Thompson S.G., Collins R., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140.
6. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
7. Wilson P.W., Nam B.H., Pencina M., D'Agostino R.B., Benjamin E.J., O'Donnell C.J. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005, 165:2473-2478.
8. Il'yasova D., Colbert L.H., Harris T.B., Newman A.B., Bauer D.C., Satterfield S., et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005, 14:2413-2418.
9. Heikkila K., Harris R., Lowe G., Rumley A., Yarnell J., Gallacher J., et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009, 20:15-26.
10. Lee C.C., Adler A.I., Sandhu M.S., Sharp S.J., Forouhi N.G., Erqou S., et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 2009, 52:1040-1047.
11. Dehghan A., van H.M., Sijbrands E.J., Stijnen T., Hofman A., Witteman J.C. Risk of type 2 diabetes attributable to C-reactive protein and other risk factors. Diabetes Care 2007, 30:2695-2699.
12. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziano J.M., Ridker P.M. C-reactive protein and the risk of developing hypertension. JAMA 2003, 290:2945-2951.
13. Kravitz B.A., Corrada M.M., Kawas C.H. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement 2009, 5:318-323.
14. van Durme Y.M., Verhamme K.M., Aarnoudse A.J., Van Pottelberge G.R., Hofman A., Witteman J.C., et al. C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 179:375-382.
15. Dahl M., Vestbo J., Zacho J., Lange P., Tybjaerg-Hansen A., Nordestgaard B.G. C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax 2011, 66:197-204.
16. Lacativa P.G., Farias M.L. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol 2010, 54:123-132.
17. Walsh N.C., Crotti T.N., Goldring S.R., Gravallese E.M. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005, 208:228-251. [228-51].
18. Gough A.K., Lilley J., Eyre S., Holder R.L., Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994, 344:23-27.
19. Lane N.E. Therapy insight: osteoporosis and osteonecrosis in systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006, 2:562-569.
20. Bernstein C.N., Blanchard J.F., Leslie W., Wajda A., Yu B.N. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000, 133:795-799.
21. Clowes J.A., Riggs B.L., Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005, 208:207-227. [207-27].
22. Lencel P., Magne D. Inflammaging: the driving force in osteoporosis?. Med Hypotheses 2011, 76:317-321.
23. de P.P., Cooper M.S., Buckley C.D. Association between bone mineral density and C-reactive protein in a large population-based sample. Arthritis Rheum 2012, 10.
24. Ding C., Parameswaran V., Udayan R., Burgess J., Jones G. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 2008, 93:1952-1958.
25. Koh J.M., Khang Y.H., Jung C.H., Bae S., Kim D.J., Chung Y.E., et al. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int 2005, 16:1263-1271.
26. Cauley J.A., Danielson M.E., Boudreau R.M., Forrest K.Y., Zmuda J.M., Pahor M., et al. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res 2007, 22:1088-1095.
27. Schett G., Kiechl S., Weger S., Pederiva A., Mayr A., Petrangeli M., et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006, 166:2495-2501.
28. Pasco J.A., Kotowicz M.A., Henry M.J., Nicholson G.C., Spilsbury H.J., Box J.D., et al. High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA 2006, 20(296):1353-1355.
29. Nakamura K., Saito T., Kobayashi R., Oshiki R., Oyama M., Nishiwaki T., et al. C-reactive protein predicts incident fracture in community-dwelling elderly Japanese women: the Muramatsu study. Osteoporos Int 2011, 22:2145-2150.
30. Ishii S., Cauley J.A., Greendale G.A., Crandall C.J., Danielson M.E., Ouchi Y., et al. C-reactive protein, bone strength, and 9-year fracture risk: data from the study of women's health across the nation (SWAN). J Bone Miner Res 2013, 10.
31. Day N., Oakes S., Luben R., Khaw K.T., Bingham S., Welch A., et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999, 80(Suppl. 1):95-103. [95-103].
32. Wareham N.J., Jakes R.W., Rennie K.L., Schuit J., Mitchell J., Hennings S., et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2003, 6:407-413.
33. Khaw K.T., Reeve J., Luben R., Bingham S., Welch A., Wareham N., et al. Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus: EPIC-Norfolk prospective population study. Lancet 2004, 363:197-202.
34. Welch A., Bingham S., Camus J., Dalzell N., Reeve J., Day N., et al. Calcaneum broadband ultrasound attenuation relates to vegetarian and omnivorous diets differently in men and women: an observation from the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Osteoporos Int 2005, 16:590-596.
35. Barbour K.E., Boudreau R., Danielson M.E., Youk A.O., Wactawski-Wende J., Greep N.C., et al. Inflammatory markers and the risk of hip fracture: the Women's Health Initiative. J Bone Miner Res 2012, 27:1167-1176.
36. Lin C.C., Kardia S.L., Li C.I., Liu C.S., Lai M.M., Lin W.Y., et al. The relationship of high sensitivity C-reactive protein to percent body fat mass, body mass index, waist-to-hip ratio, and waist circumference in a Taiwanese population. BMC Public Health 2010, 10:579. [579].
37. Pou K.M., Massaro J.M., Hoffmann U., Vasan R.S., Maurovich-Horvat P., Larson M.G., et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007, 116:1234-1241.
38. Moayyeri A., Luben R.N., Wareham N.J., Khaw K.T. Body fat mass is a predictor of risk of osteoporotic fractures in women but not in men: a prospective population study. J Intern Med 2012, 271:472-480.
39. Nilsson T.K., Boman K., Jansson J.H., Thogersen A.M., Berggren M., Broberg A., et al. Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte) stored at -70 degrees C for 8-11years. Thromb Res 2005, 116:249-254.
40. Moayyeri A., Kaptoge S., Dalzell N., Bingham S., Luben R.N., Wareham N.J., et al. Is QUS or DXA better for predicting the 10-year absolute risk of fracture?. J Bone Miner Res 2009, 24:1319-1325.
41. Stewart A., Kumar V., Reid D.M. Long-term fracture prediction by DXA and QUS: a 10-year prospective study. J Bone Miner Res 2006, 21:413-418.
42. Njeh C.F., Boivin C.M., Langton C.M. The role of ultrasound in the assessment of osteoporosis: a review. Osteoporos Int 1997, 7:7-22.
43. Agrawal A. CRP after 2004. Mol Immunol 2005, 42:927-930.
44. Marnell L., Mold C., Du Clos T.W. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 2005, 117:104-111.
45. Szalai A.J. The biological functions of C-reactive protein. Vascul Pharmacol 2002, 39:105-107.